These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23725919)

  • 1. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(3):199-207. PubMed ID: 23725919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.
    Tatsuno I; Kudou K; Kagawa T
    Cardiovasc Ther; 2015 Dec; 33(6):317-23. PubMed ID: 26222126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study.
    Mori T; Murasaki K; Hayashi K; Yokoyama Y
    J Clin Lipidol; 2022; 16(5):704-714. PubMed ID: 35871058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
    Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
    J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J; Anzalone D; Hilleman D; Catini J
    Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
    Tatsuno I
    Expert Rev Cardiovasc Ther; 2014 Nov; 12(11):1261-8. PubMed ID: 25319059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
    Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
    J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial.
    Qi L; Zhang Q; Zheng Z; Pei Z; Mao H; Jiang T; Kazei D; Kahler E; Huo Y
    Vasc Health Risk Manag; 2021; 17():571-580. PubMed ID: 34552329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study.
    Mori T; Murasaki K; Yokoyama Y
    J Clin Lipidol; 2022; 16(5):737-746. PubMed ID: 36202740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
    Bays HE; Ballantyne CM; Kastelein JJ; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2011 Sep; 108(5):682-90. PubMed ID: 21683321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.
    Schwellenbach LJ; Olson KL; McConnell KJ; Stolcpart RS; Nash JD; Merenich JA;
    J Am Coll Nutr; 2006 Dec; 25(6):480-5. PubMed ID: 17229894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ω-3 carboxylic acids for hypertriglyceridemia.
    Roth EM
    Expert Opin Pharmacother; 2015 Jan; 16(1):123-33. PubMed ID: 25480558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS
    Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
    Preston Mason R
    Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
    Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD
    Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.